Revealed the half-year results of 26 pharmaceutical commercial enterprises: 12 net profit increased

According to statistics, the total revenue of 26 pharmaceutical commercial listed enterprises in the first half of 2020 decreased by 2.29% YoY to RMB342.224 billion, while net profit increased by 3.24% YoY to RMB9.316 billion.
From a single enterprise point of view, there are 12 enterprises, including Kyushua, China Medicine, Nanjing Pharmaceuticals, Liu Medicine shares, Yan Yan Pharmaceuticals, Dasanlin, the common people, Yifeng Pharmacy, One Heart Hall, Zhejiang Zhenyuan, First Pharmaceuticals, Guofa shares, etc. to achieve a double increase in net profit.
understood that in the context of the country's in-depth promotion of the "Internet Plus" action plan, the development of the "Internet, medicine, medicine and insurance" innovation model ushered in a major period of opportunity.
driven by the "Internet Plus", the drug distribution industry and the Internet gradually move towards deep integration.
According to the data, in the first half of 2020, Kyusju Tong achieved operating income of rmb51,349 million, up 6.03% YoY;
Research Institute said that the company for the country's large-scale private pharmaceutical circulation enterprises, its national layout of efficient storage logistics operation capacity and rich upstream and downstream resources, for the company to maintain rapid development in the future has laid a better foundation and provided a strong guarantee; Gross margin business - general generation business, FBBC is on the rise, medical devices sector is still in the blue sea stage, channels high gross margin of primary hospitals, pharmacies wholesale business continued to grow rapidly, resulting in the company's profitability continues to improve, long-term performance growth rate is higher than revenue growth.
China Pharma also released its 2020 interim report on the evening of August 25, during which it achieved operating income of RMB18.809 billion, up 11.56 percent year-on-year, and net profit attributable to listed shareholders was RMB777 million, up 12.93 percent year-on-year.
According to the introduction, in the pharmaceutical business sector, Chinese medicine combined with their own market demand and network layout, rapid adjustment and optimization of product structure, increase the consistent evaluation of drugs through generic drugs, with a volume of procurement of drug varieties of development efforts, and actively develop medical devices, consumables, reagents, Chinese medicine tablets and other business, promote business cooperation in the field of IVD, and through the formation of Chongqing pharmaceutical "business complex" to strengthen the integration of varieties and coordination, further enrich the business sector business scope and connotation.
this year, Thanks to its performance in the international trade sector, China Pharma has reversed the adverse situation in the industry and achieved double growth in operating income and profits.
impact is not only the promotion of short-term profits, more importantly, the growth of international business has promoted the company's international trade channels to improve the operational capacity, accelerate the construction of the international marketing system.
addition, Nanjing Pharmaceuticals in the first half of this year also continued to promote market network coverage projects, accelerate the introduction of domestic market new drugs total more than 110 regulations, the cumulative sales amount of nearly 700 million yuan.
the same time, actively introduce the second batch of belt procurement company varieties, the introduction rate of 96.8%, the company will continue to track the third batch of national belt procurement information.
According to its semi-annual report released on the evening of August 21, the company achieved operating income of RMB18,272 million in the first half of 2020, up 2.00% YoY;
addition to this, Liu medicine shares in the first half of the retail chain pharmacy layout, the development of Internet and big data-based "new retail" business.
first half of this year, the company achieved operating income of RMB7.573 billion, up 5.22% YoY, and net profit of RMB395 million, up 10.87% YoY.
Yan Pharmaceuticals achieved operating income of RMB7,214,832,652.33 in the first half of the year, an increase of 0.58% YoY, and a net profit attributable to shareholders of listed companies of RMB130,029,913.14, an increase of 7 .22%; Dasinlin achieved operating income of RMB6.940 billion in the first half of the year, up 32.14% YoY; Net profit attributable to shareholders of listed companies was RMB595 million, up 56.21% YoY; and ordinary people achieved operating income of RMB6.687 billion in the first half of the year 20.84 percent year-on-year, net profit attributable to shareholders of listed companies was RMB336 million, up 24.39 percent year-on-year, and Yifeng Pharmacy's first-half revenue reached RMB6,293 million, up 24.65 percent from RMB5,048 million a year earlier. Net profit reached 412 million yuan, up 33.84 percent from 308 million yuan a year earlier; first-half operating income was 6.03 billion yuan, up 19.15 percent year-on-year; and net profit attributable to shareholders of listed companies was 416 million yuan. Year-on-year growth of 23.46%.
Zhenyuan's first-half operating income was RMB1,611,550,088.62, up 2.98% YoY, and net profit attributable to shareholders of listed companies was RMB47,438,320.6 0 yuan, up 2.6% YoY; First Pharma achieved operating income of RMB858 million in the first half of the year, up 38.99% YoY; and net profit attributable to shareholders of listed companies was RMB33.2699 million, up 10.21% YoY.
In addition, China National Pharmaceuticals Consistent, Heavy Medicine Holdings, Inte Group and other 3 enterprises increased income does not increase profits, Shanghai Pharmaceuticals increased profits do not increase income, Hai wang biology, National Pharmaceuticals shares, Ruikang Pharmaceuticals, Jiashetang, People's Tongtai, Tongjitang, Tai'anTang, Celeste, Huatong Pharmaceuticals, Kai Kai Industrial and other 10 enterprises net profit double-down.